REGN vs XYL · P/E 14, rev $4.29B vs P/E 27, rev $4.46B
Regeneron Pharmaceuticals Inc (REGN) versus Xylem Inc (XYL) — a side-by-side from cached financials, not a winner call.
Regeneron Pharmaceuticals Inc (REGN) is a biotechnology company listed on US.
Xylem Inc (XYL) is a specialty industrial machinery company listed on NYSE.
Latest reported REGN revenue for 2026-06-30 was $4.29B. Net income was $1.30B. Revenue was up 19.0% from 2026-03-31 to 2026-06-30. REGN currently screens at market cap $59.10B and trailing P/E 13.9.
Latest reported XYL revenue for 2026-06-30 was $4.46B. Net income was $456.0M. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
REGN currently screens at market cap $59.10B and trailing P/E 13.9. XYL currently screens at market cap $26.22B and trailing P/E 27.4.
Not investment advice. Open the REGN and XYL stock pages for the full models.
Not investment advice.